The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
This study was previously posted by Sage Therapeutics. In December 2024, sponsorship of the trial was transferred to Biogen.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
19
Administered as capsules
Sage Investigational Site
Atlanta, Georgia, United States
Sage Investigational Site
Decatur, Georgia, United States
Sage Investigational Site
Flowood, Mississippi, United States
Sage Investigational Site
Cincinnati, Ohio, United States
Plasma Concentrations of Zuranolone
PK Parameters of Zuranolone will be assessed.
Time frame: At multiple timepoints post dose on Days 1, 8 and 15
Percentage of Participants With at Least one Treatment Emergent Adverse Event (TEAE)
Time frame: Up to 42 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.